PYX-201

DRUG2 trials

Sponsors

Pyxis Oncology, Inc

Conditions

Advanced Solid TumorAdvanced Solid TumorsSolid Tumor

Phase 1

A Study of PYX-201 in Advanced Solid Tumors

RecruitingNCT05720117

Pyxis Oncology, IncAdvanced Solid Tumor, Solid Tumor

Start: 2023-03-14End: 2028-06-30Target: 330Updated: 2026-06-30

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

RecruitingNCT06795412

Pyxis Oncology, IncAdvanced Solid Tumors

Start: 2025-04-15End: 2027-12-06Target: 220Updated: 2026-09-02

Related Papers

Development of a Novel Immunohistochemistry Assay to Characterize EDB+FN Protein Expression in Solid Tumors.

2026-07-30

Abstract 4406: Mouse analog of micvotabart pelidotin, an antibody-drug conjugate targeting extradomain-B of fibronectin, demonstrates anti-tumor efficacy in an immunotherapy-refractory syngeneic head and neck squamous cell carcinoma model

Cancer Research2026-04-03

Abstract A117: Development of multiplex immunofluorescence workflows for characterizing tumor-immune and stromal compartments for pharmacodynamic assessments of solid tumors

Molecular Cancer Therapeutics2025-10-22

Abstract A112: Micvotabart pelidotin induces immunogenic cell death markers and activates tumor immune cells in pre-clinical studies

Molecular Cancer Therapeutics2025-10-22

Abstract A113: Micvotabart pelidotin, a non-cellular targeting ADC, remodels the tumor microenvironment in tumors from participants in a phase 1 dose escalation study

Molecular Cancer Therapeutics2025-10-22

Abstract A115: Mouse analog of micvotabart pelidotin sensitizes a refractory syngeneic breast cancer model to anti-PD1 therapy

Molecular Cancer Therapeutics2025-10-22

Abstract A116: Characterization of micvotabart pelidotin target binding properties and extracellular payload release

Molecular Cancer Therapeutics2025-10-22

Abstract A114: Micvotabart pelidotin, an ADC targeting non-cellular EDB+FN, induces an immune response in tumors from participants in a phase 1 dose escalation study

Molecular Cancer Therapeutics2025-10-22

Abstract 3120: Evaluation of PYX-201, an EDB+FN-targeting ADC, in a comprehensive PDX mini-trial study enables identification of gene signatures associated with anti-tumor activity

Cancer Research2025-04-21

Abstract 3137: The combination of anti-PD1 and a mouse analog of PYX-201, an antibody-drug conjugate targeting the extra-domain B splice variant of fibronectin (EDB+FN), shows greater anti-tumor efficacy than either treatment alone

Cancer Research2025-04-21

Abstract 742: PYX-201, a stroma-targeting ADC composed of an anti-EDB+FN antibody conjugated to Auristatin0101, demonstrates strong anti-tumor efficacy across multiple human cancer indications in pre-clinical PDX tumor models

Cancer Research2024-03-222 citations

762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors

Regular and Young Investigator Award Abstracts2023-10-312 citations